Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease

Abstract

Cerebrospinal fluid (CSF) concentrations of amyloid-β (Aβ) 1-38, 1-40, 1-42, total-tau and phospho-tau in samples from 156 patients with Alzheimer’s disease (AD) (n = 44), depressive cognitive complainers (DCC, n = 25) and various other forms of non-Alzheimer dementias (NAD, n = 87) were analyzed by electrochemiluminescence and enzyme linked immunosorbent assay, respectively. A significant decrease of CSF Aβ1-42 was the most powerful single marker for differentiation of AD from DCC, yielding accuracies of beyond 85%. Increased p-tau and the ratio Aβ1-42/Aβ1-38 yielded accuracies of beyond 80 and 85%, respectively, to discriminate AD versus NAD. Combining p-tau with Aβ1-42/Aβ1-38 resulted in a sensitivity of 94% for detection of AD and 85% specificity for excluding NAD. Decreased CSF Aβ1-42 represents a core biomarker for AD. The lack of specificity for exclusion of NAD can be most effectively compensated by the ratio Aβ1-42/Aβ1-38. The ratio Aβ1-42/Aβ1-38/p-tau powerfully discriminates AD versus NAD and fulfils the accuracy requirements for an applicable screening and differential diagnostic AD biomarker.

DOI: 10.1007/s00702-008-0177-6

5 Figures and Tables

0200400200920102011201220132014201520162017
Citations per Year

1,084 Citations

Semantic Scholar estimates that this publication has 1,084 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Welge2008CombinedCT, title={Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease}, author={Volker Welge and Oliver Fiege and Piotr Lewczuk and B. A. Mollenhauer and Hermann Esselmann and H. Klafki and Stefanie Wolf and Claudia Trenkwalder and Markus Otto and Johannes Kornhuber and Jens Wiltfang and Mirko Bibl}, journal={Journal of Neural Transmission}, year={2008}, volume={116}, pages={203-212} }